AstraZeneca completes divestment of Imdur

RNS Number : 9466W

AstraZeneca PLC

03 May 2016

 

ASTRAZENECA COMPLETES DIVESTMENT OF IMDUR

TO CHINA MEDICAL SYSTEM HOLDINGS

AstraZeneca today announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190 million for the rights to Imdur.

Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of $57 million in 2015. Income from the agreement will be reported as Core Other Operating Income.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Neil Burrows	UK/Global	[phone]
Vanessa Rhodes	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Enquiries
UK
Thomas Kudsk Larsen		[phone]
Eugenia Litz	RIA	[phone]
Nick Stone	CVMD	[phone]
Craig Marks	Finance	[phone]
Christer Gruvris	Consensus Forecasts	[phone]
US
Lindsey Trickett	Oncology, ING	[phone]
Mitch Chan	Oncology	[phone]
Dial / Toll-Free		[phone]

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

03 May 2016

-ENDS-

 

END

 

 

MSCBIGDUBBGBGLD